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ABSTRACT 
As the number of contact‐lens wearers rises worldwide, Pseudomonas aeruginosa (PA) keratitis is attracting 
more attention as a major public health issue. Corneal lesions of PA, being the most intimidating 
complication of contact‐lens wearer, can progress rapidly in spite of local antibiotic treatment, and may 
result in perforation and the permanent loss of vision. One of the explanations proposed for the evasion of 
the pathogen from immune responses of the host as well as antibacterial treatment is the fact that invasive 
clinical isolates of PA have the unusual ability to invade and replicate within surface corneal epithelial cells. 
In this manner, PA is left with an intracellular sanctuary. Endophthalmitis, albeit rare, is another ophthalmic 
infection faced by the challenge of drug delivery that can be potentially catastrophic. The present 
hypothesis is that nanoparticles can carry anti‐pseudomonas antibiotics (e.g. ceftazidime) through the 
membranes, into the “hidden zone” of the pathogen, hence being an effective and potent therapeutic 
approach against pseudomonas keratitis and endophthalmitis. 
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INTRODUCTION  
It has been projected that nearly 125 million people worldwide, 
wear contact lenses [1]. Microbial keratitis is the most 
intimidating complication of the contact-lens wearer. The 
prodigious population at risk brings about this complication as 
an important public issue. Pseudomonas aeruginosa [PA], a 
virulent gram-negative bacterium, has persistently been 
reported as the most frequent aetiology of contact lens-related 
microbial keratitis. Among people with contact lens keratitis, PA 
accounts for the largest mean diameter of corneal ulcers, the 
highest mean number of days in hospital, the greatest mean 
number of outpatient visits, and the poorest visual acuity 
outcome [2]. PA is sensitive to ceftazidime, ciprofloxacin, and 
amikacin [3]. This topical treatment involves applying antibiotic 
eye drops every 5 min for 1 h and then every 15 to 30 min for 
48 h or longer, which is an obviously demanding regimen of 
treatment that necessitates hospitalisation [4]. Despite topical 
antibiotic treatment, PA corneal ulcers may progress, and 
eventually, perforation may occur, making surgical intervention 
necessary [5]. A new therapeutic approach requiring less 
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frequent applications of topical antibiotics whilst enhancing the 
efficacy has been the objective of many researches. 
The cornea is not the only territory in ophthalmology where PA 
can be a real challenge. Deeper in the eye the problem gets 
even more serious. Endophthalmitis is a rare but catastrophic 
complication of intraocular surgery and penetrating injuries. 
The frequency distribution of the microorganisms isolated in 
different case series varies significantly. But in most, if not all, 
series, a significant relationship between gram-negative isolates 
[led by PA] and poor visual outcome has been reported [6]. 
Intravitreal administration of antibiotics, although quite 
invasive, is the mainstay of treatment of acute endophthalmitis, 
due to the poor ocular penetration of antibiotics administered 
by alternative routes.  
Systemically administered drugs have poor access to the retina 
and vitreous cavity because of the blood-aqueous and blood-
retinal barriers. On the other hand, the topical instillation of 
conventional drugs usually yields low bioavailability. 
Physiological mechanisms, such as blinking and tear drainage, 
reduce the residence time of topically-applied drugs. Eye drops 
placed onto the ocular surface are washed away in less than 30 
s after instillation [7, 8]. Furthermore, sealing the corneal 
epithelium by means of annular tight junctions [zonula 
occludens] leaves the cornea as a major ocular barrier that is 
almost impermeable to any substance larger than 500Da [9, 
10]. Most of the commonly used topical drugs are larger than 
that and, consequently, do not cross the cornea. Although most 
of the commonly used topical drugs can permeate throughout 
the conjunctiva and the underlying sclera it is generally 
believed to be a “non-productive passage” [11]. Altogether, the 
existence of impermeable cell barriers along with the 
physiological processes permits less than 5% of topically 
administered drugs to reach intraocular tissues [12]. 
 
HYPOTHESES 
A new solution 
It has been well-established that invasive clinical isolates of PA 
have the unusual ability to invade and replicate within surface 
corneal epithelial cells [13]. Since commonly used topical anti-
microbial agents [such as aminoglycosides] have a limited 
penetration into the cornea, PA is left with an intracellular 
sanctuary [14]. Drug delivery becomes even more difficult in 
the case of endophthalmitis. Considering the vast variety of 
novel drug delivery systems which are in our armamentarium 
nowadays, the following hypothesis is presented: anti-
pseudomonas nanoparticles can effectively reduce sequels of 
pseudomonas keratitis/endophthalmitis. The transformation of 
conventional dosage forms of antibiotics to nanoparticles and 
nanosuspensions may improve drug efficacy, safety and 
bioavailability, as well as patient compliance [15]. 
 
DISCUSSION 
Nanoparticles [more properly designated as colloidal carriers] 
consist of 1µm or smaller particles, suspended in an aqueous 
solution. This term can refer to micelles, emulsions, 
nanospheres, nanocapsules and liposomes [16]. Intensive 
research in recent decades has investigated the effect of 
colloidal carriers on the transcorneal penetration of a wide 
variety of therapeutic large, poorly water-soluble molecules. 
Kassem et al. [17] demonstrated the enhanced absorption and 
potency of glucocorticoid-associated nanosuspensions instilled 
into the lower cul-de-sac of rabbits by measuring the increase 
in intraocular pressure [IOP]. Calvo [18] has shown that 
colloidal particles of indomethacin were taken up preferentially 
by the corneal epithelial cells through endocytosis. Resembling 
a reservoir, the cornea then releases the drug to the adjacent 
tissues. Calvo and co-workers [19, 20] have also made PCL 
nanocapsules containing cyclosporine. After topical 
administration, these capsules were taken up by corneal 
epithelial cells and achieved corneal levels of cyclosporine that 
were five times higher than when using a 10mg/ml cyclosporine 
oily solution. Losa et al. revealed that nanoparticle formulations 
of amikacin, using Dextran 70000 as a stabiliser, can lead to a 
significant increase of the antibiotic concentration, not only in 
the cornea but also in the aqueous humor [21]. Nanoparticle-
mediated delivery not only overcomes the corneal epithelium 
barrier but it can also prolong the residence time of a drug in 
the pre-corneal tear film layer, hence reducing the dosage 
frequency [22].  These evidences, among others, support the 
idea that nanoparticle formulations of antibiotics may be the 
long-sought key in the treatment of PA 
keratitis/endophthalmitis.  
 
Recommendation for experimental and clinical evaluation 
Although the hypothesis presented here is based on promising 
theoretical predictions and experimental studies, the authentic 
value of anti-pseudomonas nanoparticles in decreasing PA 
keratitis/endophthalmitis morbidities can only be evaluated in 
well-designed experimental animal models and subsequent 
clinical trials. Among anti-pseudomonas antibiotics, ceftazidime 
may be a good candidate in this regard, since reports of the 
successful preparation of its nano- and micrometric particles 
have been published recently [23]. Moreover, if one is not 
familiar with animal models of experimental PA 
keratitis/endophthalmitis, some good experimental models 
employed to quantitatively determine the bactericidal 
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properties of new formulations or drugs can be readily found in 
the literature [24-27]. 
 
CONCLUSION 
If the present hypothesis holds, there is an effective 
complement, or even an alternative, to currently available 
topical antibiotics for the prevention of devastating sequels of 
PA keratitis. The main advantages of the suggested method 
would be less frequent topical applications of antibacterial 
therapies and, even more importantly, its ability to improve 
outcomes and potentially lessen the likelihood that infection 
progresses to more serious eye pathology. In the case of 
endophthalmitis, the implication would be that a non-invasive 
alternative, perhaps the topical application of nano-drugs, to 
the intraviterous administration of the antibiotics, is under way. 
This idea may also be noteworthy from a cost-effectiveness 
perspective as it may lead to the invention of a probably 
cheaper (by shortening the period of hospitalisation or by 
preventing the complications needing cornea transplantation) 
route of therapy for PA-related dilemma in ophthalmology. 
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